Promising Clinical Data for DeltaRex-G Gene Therapy Announced at ESMO 2026
News related to:The Sarcoma Oncology Center · 2 min read
The Sarcoma Oncology Center announced promising clinical data for its gene therapy, DeltaRex-G, at the European Society for Medical Oncology (ESMO) 2026 conference in Madrid, Spain. The data demonstrated significant clinical benefits and survival improvements in advanced, chemoresistant sarcomas, as well as in pancreas, breast, and ovarian cancers.
The study involved a comprehensive tumor biomarker screening of 332 samples at the Sarcoma Oncology Center/Cancer Center of Southern California. The results showed that 100% of the samples exhibited enhanced CCNG1 expression. Specifically, 22% of the samples (n=74) showed high expression, 39% (n=131) medium-high, 35% (n=115) medium-low, and 4% (n=12) low expression.
The clinical trial included a diverse patient population. Of the tested tumor samples, 88.6% (n=294) were sarcomas, 2.7% (n=9) were invasive ductal carcinoma of the breast, 0.9% (n=3) were pancreatic ductal adenocarcinoma (PDAC), and 7.8% (n=26) were other cancer types, including serous ovarian adenocarcinoma.
Among the evaluable patients, a 50% partial response rate was observed, with one patient achieving a partial response after receiving DeltaRex-G combined with FDA-approved drugs as a first-line treatment. The overall clinical benefit rate reached 90% (9/10 patients).
The safety profile of DeltaRex-G was also encouraging. No treatment-related adverse events of Grade 3 or higher were reported.
In terms of survival outcomes, the median progression-free survival (PFS) was 6.7 months (95% CI: 1.875-12.039) for sarcomas and 7.8 months (95% CI: 1.875-14.770) across all cancer types. The overall survival (OS) median reached 18.7 months (95% CI: 11.151-18.684) for sarcomas and 14.8 months (95% CI: 8.322-18.684) across all pooled cancer types.
DeltaRex-G, invented by Drs. Erlinda M. Gordon and Frederick L. Hall, is an investigational tumor-targeted gene therapy vector designed to inhibit the CCNG1 proto-oncogene pathway, disrupting tumor growth and survival in hard-to-treat solid malignancies. The therapy's mechanism of action is detailed in a review published in Cancers 2025, 17, 1125, and further research is available in Molecular Therapy Oncology 201, doi: 10.1016/j.omto.2018.118.
The Sarcoma Oncology Center, based in Santa Monica, California, provides multi-disciplinary, experimental, and advanced cancer care, pioneering novel clinical protocols and targeted therapies for sarcomas and solid tumors. The Aveni Foundation, a non-profit organization dedicated to accelerating the development of gene therapies and turning cutting-edge biotechnology research into accessible treatments for patients with advanced cancers, supports the center's work.